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CASE REPORT
Concurrent Chagas’ disease and borderline 
disseminated cutaneous leishmaniasis:   The role 
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Abstract: The occurrence of mixed infections of Trypanosoma cruzi and Leishmania spp. is 
becoming a common feature in Central and South America due to overlapping endemic areas. 
Unfortunately, the possibilities for treating ﬂ  agellated kinetoplastid infections are still very 
limited and most of the available drugs exhibit severe side effects. Although the development 
of new drugs for Leishmania has markedly improved in the last years, the tendency is still to 
employ antimonial compounds. On the other hand, treatment for Chagas’ disease is only avail-
able for the acute phase with no effective therapeutical options for chronic stage disease. The 
following case report substantiates the recently discovered effect of amiodarone as a noncon-
ventional antiparasitic drug, particularly against Leishmania, breaching a new perspective in 
the therapeutic management of these important infectious parasitic diseases.
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Introduction
Leishmania and Trypanosoma are digenetic ﬂ  agellated kinetoplastid protozoa impli-
cated as the causative agents of two of the most important parasitic endemic diseases 
in Central and South America: Leishmaniasis and Chagas’ disease, respectively 
(Mendes et al 2007). American cutaneous leishmaniasis comprises a spectrum of clini-
cal syndromes characterized by two polar forms: localized cutaneous leishmaniasis, 
which is observed in patients which develop a competent immune response against 
the parasite, and diffuse cutaneous leishmaniasis characterized by extensive lesions 
and a speciﬁ  c T cell immunodeﬁ  ciency in the host (Convit 1996). Intermediate forms 
of the disease (mucocutaneous and borderline disseminated cutaneous leishmaniasis) 
are rare entities that often reﬂ  ect a partial immunodeﬁ  ciency with an exaggerated or 
even absent delayed type hypersensitivity respectively (Convit et al 1993; Silveira 
2004). On the other hand, American trypanosomiasis or Chagas’ disease caused by 
the hemoﬂ  agellate protozoa Trypanosoma cruzi, is a biphasic disease that exhibits an 
acute as well as a chronic phase, the latter with severe and fatal complications such 
as chagasic cardiomyopathy (Dias et al 1956).
Conventional therapy of leishmaniasis comprises the utilization of pentavalent anti-
monials demanding a careful monitoring of the renal and liver function, so as a previous 
cardiac evaluation that must include an electrocardiographic study due to the known 
cardiotoxicity of antimonials (Murray et al 2005; Schwartz 2006). For Chagas’ disease, 
current treatment of the acute phase is based on nitrofurans (nifurtimox) and nitroimid-
azoles (benznidazole), nevertheless, these compounds have proven to be of limited 
efﬁ  cacy in chronic stages and their use is restricted because of their important toxic side 
effects (Urbina and Docampo 2003). Systematic reviews of controlled trials including 
asymptomatic and symptomatic patients have revealed that there is insufﬁ  cient data to Therapeutics and Clinical Risk Management 2008:4(3) 660
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provide evidence that currently available trypanosomatidal 
therapy or any other drug used for the symptomatic treatment 
of chagasic cardiomyopathy can modify clinical outcomes in 
chronic Chagas disease (Marin-Neto et al 2007). However, 
nowadays the development of new drugs and studies on the 
anti-trypanosomatidal effect of some old compounds such as 
amiodarone, have opened new insights in the therapeutical 
approach and management of these parasitic diseases.
The following case reveals the potential utility of amioda-
rone, not only for the symptomatic treatment of arrhytmias in 
Chagas’ disease and its possible anti-parasitic effect against 
T. cruzi, but, in the treatment of other kinetoplastid protozoal 
infections such as leishmaniasis.
Case report
A 74 year-old male agriculture worker from the central 
western region of the Venezuelan plains (Llanos) was trans-
ferred to our center for further management of his cutaneous 
condition. The infection had started one year previous to his 
admission with a primary skin lesion in the form of a ﬁ  rm 
erythemathous nodule that evolved to an irregularly shaped 
inﬁ  ltrated plaque located in his left lower extremity. After two 
months, the plaque ulcerated with the concomitant appear-
ance of multiple small nodular metastatic lesions.
Upon admission and initial evaluation, he was found to 
have a 7 × 5 × 4.5 cm ulcer with heavily inﬁ  ltrated borders and 
multiple satellite inﬁ  ltrated nodular and acneiform lesions 
measuring 2 cm in diameter with the largest located at only 
5 cm from the primary ulcerated lesion (Figures 1 and 2). 
A Giemsa-stained skin smear revealed the presence of 
few amastigotes in the lesions (Figure 3) and delayed type 
hypersensitivity (DTH) skin-test was negative. Histological 
sections of the lesions revealed a vacuolated granuloma 
exhibiting large collections of vacuolated and heavily para-
sitized macrophages surrounded by a lympho plasmacytic 
inﬁ  ltrate (Figure 4). Further parasite culture and typiﬁ  cation 
conﬁ  rmed the presence of Leishmania (Viannia) braziliensis 
as the etiologic agent.
Figure 1 Ulcerated lesion with partial re-epithelization after the tenth day of treatment.Therapeutics and Clinical Risk Management 2008:4(3) 661
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The past medical history of the patient was otherwise 
unremarkable, except for episodes of dispnea, ortopnea, and 
palpitations over the last three months. The physical examina-
tion revealed jugular vein distention, prominent audible S3 
heart sound, and a laterally displaced cardiac apex; rales were 
audible in both lung bases and mild pitting edema was evident 
in lower extremities; the rest of the physical examination was 
unremarkable. A complete cardiovascular workup was initi-
ated to asses the cause of the symptoms. The chest radiography 
revealed cardiomegaly and discrete bilateral pleural effu-
sions. On echocardiography focal segmental abnormalities 
were evident mainly in the posterioinferior aspect of the left 
ventricle with moderate hypokinesia. A conventional 12-lead 
electrocardiogram (EKG) and a 24-hour Holter monitoring 
demonstrated the presence of a non-sustained ventricular 
tachycardia and ventricular extrasystoles.
Complete blood count was unremarkable, chemistry panel 
revealed: urea nitrogen: 21.0 mg/dl, creatinine: 2.3 mg/dl, 
sodium: 136 mEq/L, potassium: 4.0 mEq/L. Because the 
patient came from a highly endemic area of Chagas’ dis-
ease he was tested for this illness, resulting positive in the 
Machado-Guerreiro complement-ﬁ  xation test which was 
then conﬁ  rmed by enzyme-linked immunosorbent assay with 
recombinant highly speciﬁ  c antigens.
Due to his underlying cardiovascular condition the 
possibility of initiating pentavalent antimonial therapy for 
Leishmania was discarded temporarily until stabilization, 
and the patient was immediately initiated on Amiodarone 
with a loading regimen of 1600 mg daily for the ﬁ  rst four 
days and a further maintenance dose of 800 mg/day for 
three weeks; adequate control of the ventricular arrhytmyas 
was achieved, and patient’s CHF condition improved with 
supportive symptomatic treatment. Strikingly, the cutaneous 
lesions also started to improve despite the absence of speciﬁ  c 
antileishmanial therapy; the ulcers started to re-epithelize 
since the fourth day, and after ﬁ  fteen days parasitic forms 
were not found on microscopic examination of control smears 
and biopsies. Patient was discharged from our center and 
Figure 2 Satellite disseminated acneiform lesions with moderate perilesional inﬁ  ltration.Therapeutics and Clinical Risk Management 2008:4(3) 662
Mondolﬁ   et al
remitted to the corresponding dermatology clinic in his region 
who informed us that the ulcer had completely healed after 
one month and that after one year no new lesions developed 
with serially negative control biopsies (read in our laboratory) 
declaring the clinical cure of this patient.
Spirometry testing and thyroid function tests were per-
formed at the beginning and after the period of treatment 
remaining under normal limits. The patient was remitted 
to a cardiology center for further follow up of his Chagas’ 
disease continuing his symptomatic treatment and a low 
dose (200 mg/day) regimen of amiodarone for prevention of 
arrhytmias, with a notable reduction in his congestive heart 
failure exacerbation episodes (personal communication from 
the regional sanitary ofﬁ  ce).
Discussion
Human mixed infections of Leishmania spp. and T. cruzi are 
becoming a common clinical feature in Central and South 
America due to overlapping endemic areas of both diseases 
(Bastrenta et al 2003). Secondary invasion of the parasite’s 
ecological habitat because of degradation of the local envi-
ronment, due to the growing population density extending to 
periurban regions is the main reason of the increment in the 
number of cases which can initially, and for long periods of 
time, be asymptomatic (Mendes et al 2007).
Following an initial acute phase in which signs and symp-
toms are usually nonspeciﬁ  c, Chagas’ disease enters a chronic 
phase that can remain asymptomatic for periods of years or even 
throughout the lifetime (Dias et al 1956). Most cases, as the 
one we report, are incidentally diagnosed when consulting for 
other reasons. Unfortunately, by the time patients with Chagas’ 
disease are diagnosed in the chronic phase, the therapeutical 
options are of limited effectiveness (Croft et al 2005). In this 
case the patient had begun to exhibit cardiovascular symptoms 
which in addition to his epidemiological background led to the 
suspicion and conﬁ  rmation of T. cruzi infection with chagasic 
cardiomyopathy. Nevertheless, this patient consulted speciﬁ  -
cally because of his cutaneous lesions.
Some authors state that isolated ulcers as occur in cases 
of localized cutaneous leishmaniasis are usually self-limited 
and that dangers of treatment should be balanced against the 
possibility of spontaneous cure (Seear 2000); however in our 
experience, self-healing lesions are rare, and extremely often 
are associated to secondary infections that limit the spontane-
ous healing of the ulcers. On the other hand, cases of borderline 
disseminated cutaneous leishmaniasis despite aggressive local 
measures are virtually incurable with out speciﬁ  c chemo-
therapy and have not been reported in the literature.
After being diagnosed with borderline disseminated cuta-
neous leishmaniasis, the underlying cardiologic condition 
of the patient imposed a challenge at the time to treat with 
pentavalent antimonials due to the associated cardiotoxic 
effects of these drugs – such as development of ventricular 
tachyarrhythmias associated with prolongation of the elec-
trocardiographic rate-corrected QT interval (Lawn et al 
2006) – which could have potentially aggravated the patient’s 
condition; in this sense the use of antimonials was discarded 
and no other antileishmanial medication was initiated.
Amiodarone which is a versatile antiarrhytmic agent, 
chieﬂ  y class III but with also strong class I and ancillary class 
II and IV activity (Opie 2005) was initiated not only to control 
the patients arrhythmia as part of the symptomatic treatment 
for his Chagas’ disease, but also in an attempt to secondarily 
Figure 3 Giemsa-stained skin smear revealing parasites disposed in groups, note the 
typical round nucleus and rod-shaped kinetoplast in the body of the amastigotes.
Figure 4 Detail of the histological section standing out the diffuse macrophagic 
granuloma invaded by numerous lymphoid cells and presence of amastigotes contained 
in the vacuolated macrophages (Hematoxilin-Eosin x400).Therapeutics and Clinical Risk Management 2008:4(3) 663
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treat his leishmaniasis, by taking advantage of the recently 
described properties of this drug as an antiparasitic drug.
The role of amiodarone as an antimicrobial agent was 
recently revealed by Courchesne (2002) who characterized this 
compound’s broad fungicidal activity by inducing a MID1-
dependent rise in free cytoplasmic calcium in the baker’s yeast 
Saccharomyces cerevisiae (Courchesene 2003) and by disrupt-
ing calcium hemostasis (Gupta 2003). Furthermore its use as an 
antiprotozoal agent has been newly studied after being proved 
to be effective against both proliferative stages of T. cruzi in a 
comparable manner to its antifungal activity (Benaim 2006). 
Amiodarone acts by interfering with sterol biosynthesis of the 
parasites membrane and also by inducing a rapid raise in free 
cytoplasmic calcium levels from intracellular compartments 
as well as from the mitochondria, provoking a collapse of the 
mithocondrial membrane potential (Benaim 2006).
On the other hand, the efﬁ  cacy of amiodarone in Leishmania 
infection may be favored by its pharmacokinetic characteristics, 
being the most prominent: its highly lipid-soluble nature, exten-
sive tissue distribution and its important skin excretion (Opie 
2005); the latter attribute ensuring its adequate delivery into the 
site of infection with Leishmania in this patient. Nonetheless, 
caution has to be exercised when considering treatment with 
amiodarone because of its restraining side effects such as car-
diotoxicity, thyroid disfunction and pulmonary ﬁ  brosis (Opie 
2005). However, structural modiﬁ  cations in the amiodarone 
molecule have led to the development of new drugs such as 
dronedarone, which lack these severe side effects and provide 
new and more secure therapeutical options (Singh 2006).
Considering that Trypanosoma and Leishmania as related 
organisms share similar biosynthetic pathways and metabolic 
processes, it is also possible that amiodarone’s anti T. cruzi 
effects could also be effective against the Leishmania parasite 
sharing the same underlying molecular mechanisms. The fact 
that this patient exhibited a clinical parasitological cure under 
treatment with amiodarone and no other antileishmanial drug 
sustains this statement and reinforces the efﬁ  cacy of this 
chimerical drug as antitrypanosomatidae.
Concluding remarks
Finally, to our knowledge, this is the ﬁ  rst case report in which 
parasitism by Leishmania is successfully treated with this 
nonconventional antiparasitic drug; the clinical outcome of 
this patient appears to indicate that amiodarone exhibits a 
broad spectrum antiprotozoal activity in addition to its well 
known antifungal action. Taking into consideration that pro-
tozoan pathogens cause an increased morbidity and mortality 
among millions of humans, especially in developing, tropical, 
and subtropical countries, the use of amiodarone or its new 
analogues offer a whole new approach in the treatment of leish-
maniasis and other parasitic diseases. Further research on the 
potential antileishmanial effect of amiodarone on experimental 
models would be timely in order to reveal the underlying 
mechanisms of this possible new therapeutic option.
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